Skip to main content

Hofseth Biocare ASA: APPROVAL AND PUBLICATION OF PROSPECTUS SUPPLEMENT FOLLOWING AGREEMENT WITH DKSH

Written by Customer Service on . Posted in Public Companies.

NOT FOR DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE’S REPUBLIC OF CHINA OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFULReference is made to the stock exchange announcements from Hofseth BioCare ASA (the “Company”) on 4 December 2020 regarding approval and publication of the Company’s prospectus dated 3 December 2020 (the “Prospectus”) and on 7 December 2020 regarding the commencement of the subscription period in a subsequent offering raising gross proceeds of up to approximately NOK 40 million (the “Subsequent Offering”).On 8 December 2020, e.g. following publication of the Prospectus, the Company published that it had entered into a distribution agreement with DKSH. The Norwegian Financial Supervisory Authority has today approved a supplement to the Prospectus (the “Prospectus Supplement”), which implements information about the distribution agreement with DKSH into the Prospectus. The information contained in the Prospectus Supplement shall be considered as an integral part of, and is to be read together with, the Prospectus.The Prospectus Supplement is published today and will, subject to applicable local securities laws, be available at www.paretosec.com/updates/transactions. The Prospectus Supplement will also be available at the offices of the Company.Pareto Securities AS acts as manager in the Subsequent Offering. Advokatfirmaet CLP DA acts as Norwegian legal counsel to Hofseth BioCare ASA.For further information, please contact:Jon Olav Ødegård, CFO at Hofseth BioCare ASA
Phone: +47 936 32 966
E-mail: joo@hofsethbiocare.noAbout Hofseth BioCare ASA:
HBC is a Norwegian biotech company that develops high-value ingredients and finished products currently targeting the consumer health market. Research is ongoing to identify the individual elements within the products that modulate inflammation and the immune response with pre-clinical studies in multiple clinics and university research labs in several countries. Lead clinical and pre-clinical candidates are in development for the protection of the Gastro-Intestinal (GI) system against inflammation, including ulcerative colitis and the orphan condition necrotising enterocolitis, as a Medical Food to help treat age-related Sarcopenia, and as a treatment for Iron Deficiency Anemia, all using peptide fractions of Salmon Protein Hydrolysate. Preclinical trial work with the oil is ongoing to ameliorate lung inflammation in eosinophilic asthma and COPD (“smokers lung”) as well as clinical work in COVID.The company is founded on the core values of sustainability, traceability and optimal utilization of natural resources. Through an innovative hydrolysis technology, HBC can preserve the quality of lipids, proteins and collagen-calcium from fresh salmon off-cuts. Hofseth BioCare’s headquarters are in Ålesund, Norway with branches in Oslo, London, Zürich, Chicago, Menlo Park and Tokyo.
HBC is listed on Euronext Expand Oslo with ticker “HBC”. More information about Hofseth BioCare at hofsethbiocare.com and facebook.com/hofsethbiocareThis information is subject to the disclosure requirements pursuant to Section 5-12 of the Norwegian Securities Trading Act

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.